Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.42 |
| ▸ | SLC6A1 known ✓ | P30531 | 3/20 | 0.41 |
| ▸ | GABRA5 known ✓ | P31644 | 3/20 | 0.41 |
| ▸ | GABRB2 known ✓ | P47870 | 3/20 | 0.41 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.41 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.41 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.38 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.38 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.38 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.38 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.38 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.38 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.38 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2035544 | 1.00 | FDPS (0.43) | FDPSITGB3ITGB2ITGB1ITGAV | |
| Hydrochloric Acid SCHEMBL643019 | 1.00 | FDPS (0.43) | FDPSITGB3ITGB2ITGB1ITGAV | |
| Hydrochloric Acid SCHEMBL17223559 | 1.00 | FDPS (0.43) | FDPSITGB3ITGB2ITGB1ITGAV | |
| SCHEMBL1476244 | 0.98 | — | — | |
| SCHEMBL288677 | 0.98 | — | — | |
| SCHEMBL288786 | 0.98 | — | — | |
| Bromide SCHEMBL9376271 | 0.96 | FDPS (0.43) | FDPSITGB3ITGB2ITGB1ITGAV | |
| Bromide SCHEMBL9376277 | 0.96 | FDPS (0.43) | FDPSITGB3ITGB2ITGB1ITGAV | |
| Hydrochloric Acid SCHEMBL16909729 | 0.94 | FDPS (0.50) | FDPSITGB3ITGB2ITGB1ITGAV | |
| Hydrochloric Acid SCHEMBL22800513 | 0.94 | FDPS (0.42) | FDPSITGB3ITGB2ITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-117659023-A | Pyridine acetamide derivative, pharmaceutical composition containing same and medical application of pyridine acetamide derivative | 苏州阿尔脉生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| CN-104619709-B | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-11-09 | — | — | CN | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| CN-104619709-A | Imidazopyridine derivatives as modulators of TNF activity | UCB PHARMA SA | 2015-05-13 | — | — | CN | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009094457-A2 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | ITGB3 3335/4885ITGA2B 1216/4885SLC6A1 3880/4885 |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | ITGB3 3111/4885ITGA2B 2355/4885SLC6A1 806/4885 |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | UGT2B7, CYP3A7, CYP3A43 | ITGB3 1907/4885ITGA2B 1518/4885SLC6A1 360/4885 |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ITGB3 3111/4885ITGA2B 2355/4885SLC6A1 806/4885 |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | ITGB3 1417/4885ITGA2B 2427/4885SLC6A1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.